We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Perils and pitfalls of retrospective clinicopathological prognostic models for individualised cancer risk prediction.
- Authors
Correa, Andres F.; Uzzo, Robert G.
- Abstract
Emerging RCC biomarkers, such as plasma or urine cell-free methylated DNA [6], are poised to change the landscape of RCC risk prediction by accurately selecting patients with residual disease, but more importantly, allowing us to measure the effect of our adjuvant treatments, taking us a step further in achieving our goal of personalised medicine. The human genome project opened our imagination towards personalised medicine, where diseases might be identified before they caused harm, and treatments could be tailored towards specific patients and their disease's genetic make-up. As a result, the 2000s saw the introduction of new and complex clinic pathological nomograms and predictive models leveraging patient and tumour factors, promising individualised and improved risk prediction over the standard TNM staging system.
- Subjects
PROGNOSTIC models; DISEASE risk factors; CELL-free DNA; CLINICAL pathology; RENAL cell carcinoma
- Publication
BJU International, 2022, Vol 130, Issue 5, p537
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.15709